The UK BioIndustry Association (BIA) and the Medicines and Healthcare products Regulatory Agency (MHRA) today publish a report following their fifth joint annual conference, Pathway of Innovation from Research to Patients, held on 11 June at the Wellcome Trust.
The event, which was attended by over 140 delegates from patients’ groups, MHRA, the National Institute for Biological Standards and Control, the life science industry, the Wellcome Trust, the Jenner Institute, academic institutions and clinical trial units, showcased the collaborative approaches between stakeholders to support innovation and to facilitate clinical development and timely access to new treatments and vaccines for patients.
Key topics of discussion included the value of a patient-centered approach in informing and accelerating drug development and lessons learnt from the unprecedented response to the recent Ebola epidemic. Establishing a patient-centred system for drug development requires a co-ordinated effort, which the UK is well placed to achieve with strong patients’ groups becoming increasingly involved in regulatory processes, health technology assessments and commissioning decisions.
The newly published report provides an overview of key discussions from the conference and a resulting set of recommendations.
Commenting on the publication of the report, Steve Bates, BIA CEO, said:
Following another successful joint conference with the MHRA, the publication of our first report from the event will provide a great lasting resource for SMEs, increasing awareness of the potential impact that patient engagement could have on regulatory pathways.
Dr Christiane Abouzeid, Head of Regulatory Affairs, BIA, commented:
The annual BIA/MHRA conference provides an excellent opportunity for the exchanging of expertise between regulators and industry, now extended through the publication of our joint report.
Dr Siu Ping Lam, Director, Licensing Division, MHRA, said:
This was a hugely productive conference. It is increasingly recognised that patients have a key role to play in regulatory decisions. This goes to the heart of MHRA’s mission of encouraging, supporting and enabling innovation”.
We will continue to use our scientific and regulatory expertise to advise industry and make drug development programmes as efficient as possible, facilitating safe and timely patient access.
The fifth annual joint BIA/MHRA conference was held on 11 June 2015 at the Wellcome Trust in London.
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks. MHRA is a centre of the Medicines and Healthcare products Regulatory Agency which also includes NIBSC and CPRD. The Medicines and Healthcare products Regulatory Agency is an executive agency of the Department of Health.
Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives. For further information, please go to www.bioindustry.org and twitter.com/BIA_UK
Jess Gray, Communications Executive
Phone: 020 7630 2197